Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.
Eli Lilly and Company (NYSE: LLY) generates frequent news across cardiometabolic health, oncology, immunology, obesity and manufacturing expansion. This page aggregates recent press releases and third-party coverage so readers can follow how Lilly’s medicines, clinical programs and corporate actions are evolving over time.
Recent updates show Lilly reporting Phase 3 results for multiple late-stage assets. In obesity and cardiometabolic health, the company has shared topline data from ATTAIN-MAINTAIN, a Phase 3 trial of orforglipron, an investigational once-daily oral GLP-1 receptor agonist, for weight maintenance after prior treatment with injectable incretin therapies. Lilly has also reported results from TRIUMPH-4, a Phase 3 trial of retatrutide, an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors, in adults with obesity or overweight and knee osteoarthritis, with co-primary endpoints in weight loss and pain reduction.
In immunology, Lilly has announced positive topline results from the TOGETHER-PsA Phase 3b trial, which evaluated concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one weight-related condition. The company reports that the combination met the primary endpoint and all key secondary endpoints, supporting an integrated approach to treating psoriatic arthritis and obesity.
Oncology news includes updated EMBER-3 data for Inluriyo (imlunestrant) as monotherapy and in combination with Verzenio (abemaciclib) in ER-positive, HER2-negative advanced breast cancer, and Phase 3 BRUIN CLL-313 results showing that Jaypirca (pirtobrutinib) significantly reduced the risk of progression or death versus chemoimmunotherapy in treatment-naïve CLL/SLL without 17p deletions.
Corporate and strategic news items cover Lilly’s planned acquisition of Ventyx Biosciences, completion of the Adverum Biotechnologies tender offer, a strategic collaboration with Aktis Oncology, and a major manufacturing investment in a new active pharmaceutical ingredient facility in Huntsville, Alabama. Investors and observers can use this news feed to monitor clinical milestones, regulatory submissions, acquisitions, collaborations, financing activities and manufacturing expansions related to LLY.
Eli Lilly (NYSE: LLY) has announced the release of Zepbound® (tirzepatide) 2.5 mg and 5 mg single-dose vials for self-pay patients with obesity. This expansion aims to meet high demand and broaden access to the medication. The vials are priced at least 50% less than other incretin medicines for obesity. Available through LillyDirect®'s self-pay channel, the 2.5 mg four-week supply costs $399, while the 5 mg dose is $549.
Zepbound, which activates both GIP and GLP-1 hormone receptors, achieved an average of 15% weight loss over 72 weeks in clinical trials. The single-dose vials are intended for adults with obesity or overweight individuals with weight-related medical problems. Lilly emphasizes the importance of using Zepbound with a reduced-calorie diet and increased physical activity.
Eli Lilly and Company (NYSE: LLY) has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024. Jacob Van Naarden, executive vice president and president of Lilly Oncology, will engage in a fireside chat at 7:45 a.m. Eastern time.
Investors and interested parties can access a live audio webcast of the presentation through Lilly's Investor website. The webcast will be available in the 'Webcasts & Presentations' section at https://investor.lilly.com/webcasts-and-presentations. For those unable to attend live, a replay of the presentation will be accessible on the same website for approximately 90 days following the event.
Eli Lilly's tirzepatide showed remarkable results in a 176-week SURMOUNT-1 Phase 3 study for long-term weight management and diabetes prevention. The drug reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight. Participants on the 15 mg dose experienced an average 22.9% decrease in body weight compared to 2.1% for placebo.
The study involved 1,032 adults with pre-diabetes and obesity or overweight. Tirzepatide, a GIP and GLP-1 receptor agonist, demonstrated sustained weight loss and significant reduction in diabetes risk throughout the treatment period. The safety profile was consistent with previous studies, with gastrointestinal-related adverse events being most common.
Eli Lilly and Company (NYSE: LLY) has announced the retirement of Marschall S. Runge, M.D., Ph.D. from its Board of Directors, effective Aug. 31, 2024. Dr. Runge, who has served on Lilly's board since 2013, is also retiring from his roles as CEO of Michigan Medicine, executive vice president for medical affairs at the University of Michigan, and dean of the Medical School on June 30, 2025. He will remain on the Medical School faculty as a professor.
During his tenure, Dr. Runge served on the board's Science and Technology Committee and Ethics and Compliance Committee, bringing decades of experience as a physician, scientist, and expert in health care faculty systems, biomedical research, clinical trial design, and patient safety. His research-driven perspective has been particularly valuable in the areas of diabetes and obesity treatments.
Eli Lilly and Company (NYSE: LLY) has successfully completed its acquisition of Morphic Holding, Inc. (NASDAQ: MORF), a biopharmaceutical company developing oral integrin therapies for treating serious chronic diseases. The acquisition, valued at $57 per share, broadens Lilly's immunology pipeline, particularly in the field of inflammatory bowel disease (IBD).
Key highlights include:
- Acquisition of Morphic's oral integrin therapies, including MORF-057, a selective oral small molecule inhibitor of α4β7 integrin for IBD
- Reinforcement of Lilly's strategy to deliver first or best-in-class therapies in gastroenterology
- Potential for researching combination treatments to better serve patients
- Delisting of Morphic's common stock from The Nasdaq Global Market
Eli Lilly and Company (NYSE: LLY) has opened the Lilly Seaport Innovation Center (LSC) in the Boston Seaport, a state-of-the-art research and development facility focused on advancing RNA and DNA-based therapies. The 346,000 square foot, 12-story building will house approximately 500 Lilly scientists and researchers, plus 200 people from Lilly Gateway Labs' companies. LSC serves as the central hub for Lilly's genetic medicines efforts and includes the first East Coast Lilly Gateway Labs location.
The facility aims to discover new drug targets for creating life-changing medicines in areas such as diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. This expansion reinforces Lilly's commitment to the Boston area and fosters collaboration with leading institutions to accelerate the development of novel medicines.
Eli Lilly (NYSE: LLY) reported Q2 2024 financial results with a 36% revenue increase to $11.30 billion, driven by strong sales of Mounjaro, Zepbound, and Verzenio. Excluding the previous year's $579 million Baqsimi sale, revenue rose by 46%. EPS surged 68% to $3.28 and 86% to $3.92 on a non-GAAP basis. The company raised its full-year revenue guidance by $3 billion and EPS guidance to $15.10-$15.60 reported and $16.10-$16.60 non-GAAP.
Pipeline progress included FDA approval of Kisunla for Alzheimer's and Jaypirca in Japan for relapsed mantle cell lymphoma, plus significant trial results for tirzepatide.
Gross margin increased by 40% to $9.13 billion, despite a 15% rise in R&D expenses. U.S. revenue grew 42%, led by Mounjaro and Zepbound, while international revenue rose 25%. Key products like Taltz and Jardiance also saw significant growth.
Financial guidance saw notable improvements, with revenue now expected between $45.4 billion and $46.6 billion. The company also announced a $5.3 billion manufacturing investment in Indiana to support pipeline medicines.
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the SUMMIT phase 3 clinical trial of tirzepatide in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. The study met both primary endpoints:
1. 38% reduction in the risk of heart failure outcomes compared to placebo
2. Significant improvements in heart failure symptoms and physical limitations
Key secondary endpoints were also met, including improved exercise capacity, reduced inflammation, and 15.7% mean body weight reduction at 52 weeks. The safety profile was consistent with previous studies. Lilly plans to submit results to regulatory agencies later this year.
Eli Lilly and Company (NYSE: LLY) has announced that it will release its second-quarter 2024 financial results on August 8, 2024. The company will host a conference call at 10 a.m. Eastern time on the same day to discuss the financial performance with investors, media, and the general public.
A live webcast of the conference call will be accessible through a link on Lilly's investor relations website. For those unable to attend the live event, a replay will be made available on the same website following the call.
GordonMD Global Investments announced that its portfolio company, Radionetics Oncology, has entered into a strategic agreement with Eli Lilly and Company (NYSE: LLY). This agreement focuses on developing targeted radiopharmaceuticals for cancer treatment.
As part of the deal, Radionetics received a $140 million upfront cash payment. Additionally, Lilly secured the exclusive right to acquire Radionetics for $1 billion upon the conclusion of an exercise period. Radionetics' innovative platform combines radiopharmaceuticals with small molecule targeting, particularly focusing on GPCRs, which hold significant potential in oncology.
Dr. Craig Gordon, CEO of GordonMD, expressed support for Radionetics' mission of advancing next-generation cancer treatments, aligning with their investment philosophy of fostering healthcare innovation.